Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years

References

• Smeland S, Bielack SS, Whelan J, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American osteosarcoma study) cohort. Eur J Cancer. 2019;109:36–50. doi:10.1016/j.ejca.2018.11.02730685685
   PubMed Web of Science ®Google Scholar
• Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol. 1994;12(12):2699–2705. doi:10.1200/JCO.1994.12.7.14227989947
   PubMed Web of Science ®Google Scholar
• Bacci G, Ruggieri P, Picci P, et al. Intra-arterial versus intravenous cisplatinum (in addition to systemic adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study. J Chemother. 1996;8(1):70–81.8835114
   PubMed Web of Science ®Google Scholar
• Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori. 1999;85(6):458–464. doi:10.1177/03008916990850060710774566
   PubMed Web of Science ®Google Scholar
• Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer. 1990;65(11):2539–2553.2337871
   PubMed Web of Science ®Google Scholar
• Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer. 1990;66(8):1703–1710. doi:10.1002/1097-0142(19900915)66:14+<1326::aid-cncr2820661405>3.0.co;2-p2208024
   PubMed Web of Science ®Google Scholar
• Jaffe N, Raymond AK, Ayala A, et al. Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the primary tumor in osteosarcoma. Cancer. 1989;63(1):63–67. doi:10.1002/1097-0142(19890301)63:5<948::aid-cncr2820630527>3.0.co;2-u2910425
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27(1):98–104. doi:10.1053/ejso.2000.105611237499
   PubMed Web of Science ®Google Scholar
• Avritscher R, Javadi S. Transcatheter intra-arterial limb infusion for extremity osteosarcoma: technical considerations and outcomes. Tech Vasc Interv Radiol. 2011;14(3):124–128. doi:10.1053/j.tvir.2011.02.00421767779
   PubMedGoogle Scholar
• Hugate RR, Wilkins RM, Kelly CM, Madsen W, Hinshaw I, Camozzi AB. Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin Orthop Relat Res. 2008;466(6):1292–1301. doi:10.1007/s11999-008-0396-z18437502
   PubMed Web of Science ®Google Scholar
• Gill M, McCarthy M, Murrells T, Silcocks P. Chemotherapy for the primary treatment of osteosarcoma: population effectiveness over 20 years. Lancet. 1988;1(8587):689–692. doi:10.1016/S0140-6736(88)91485-72895220
   PubMed Web of Science ®Google Scholar
• Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9(8):893–899. doi:10.1023/A:10083911031329789613
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.02619097774
   PubMed Web of Science ®Google Scholar
• Cullen JW, Jamroz BA, Stevens SL, et al. The value of serial arteriography in osteosarcoma: delivery of chemotherapy, determination of therapy duration, and prediction of necrosis. J Vasc Interv Radiol. 2005;16(8):1107–1119. doi:10.1097/01.RVI.0000167856.31329.F816105923
   PubMed Web of Science ®Google Scholar
• Chiu TJ, Wang JW, Chen YJ, Tang Y, Huang CH. Intraarterial cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan. Chang Gung Med J. 2009;32(1):72–80.19292942
   PubMedGoogle Scholar
• Brochtrup ED, Smee NM, Armbrust LJ, Caserto BG. Pathology in practice. Telangiectatic osteosarcoma. J Am Vet Med Assoc. 2013;242(10):1355–1357. doi:10.2460/javma.242.5.61123634678
   PubMedGoogle Scholar
• Liu JJ, Liu S, Wang JG, et al. Telangiectatic osteosarcoma: a review of literature. Onco Targets Ther. 2013;6:593–602.23745051
   PubMed Web of Science ®Google Scholar
• Angelini A, Mavrogenis AF, Trovarelli G, Ferrari S, Picci P, Ruggieri P. Telangiectatic osteosarcoma: a review of 87 cases. J Cancer Res Clin Oncol. 2016;142(10):2197–2207. doi:10.1007/s00432-016-2126-327469493
   PubMed Web of Science ®Google Scholar
• Durnali A, Alkis N, Cangur S, et al. Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol. 2013;30(3):624. doi:10.1007/s12032-013-0624-623749307
   PubMed Web of Science ®Google Scholar
• Collins M, Wilhelm M, Conyers R, et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol. 2013;31(18):2303–2312. doi:10.1200/JCO.2013.49.021923669227
   PubMed Web of Science ®Google Scholar
• Xu J, Xie L, Guo W. Neoadjuvant chemotherapy followed by delayed surgery: is it necessary for all patients with nonmetastatic high-grade pelvic osteosarcoma? Clin Orthop Relat Res. 2018;476(11):2177–2186. doi:10.1097/CORR.000000000000038729912746
   PubMed Web of Science ®Google Scholar
• Colvin MP, Curran JP, Jarvis D, O’Shea PJ. Femoral artery pressure monitoring. Use of the seldinger technique. Anaesthesia. 1977;32(5):451–455. doi:10.1111/j.1365-2044.1977.tb10048.x869144
   PubMed Web of Science ®Google Scholar
• Picci P, Bacci G, Campanacci M, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56(7):1515–1521. doi:10.1002/1097-0142(19851001)56:7<1515:AID-CNCR2820560707>3.0.CO;2-63861228
   PubMed Web of Science ®Google Scholar
• Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106–120.
   PubMed Web of Science ®Google Scholar
• Chung AE, Shoenbill K, Mitchell SA, et al. Patient free text reporting of symptomatic adverse events in cancer clinical research using the national cancer institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Am Med Inform Assoc. 2019;26(4):276–285. doi:10.1093/jamia/ocy16930840079
   PubMed Web of Science ®Google Scholar
• Liu YJ, Zhu GP, Guan XY. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48(6):554–559. doi:10.1016/j.oraloncology.2012.01.00422289637
   PubMed Web of Science ®Google Scholar
• Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72(11):3227–3238. doi:10.1002/1097-0142(19930901)72:5<1657::aid-cncr2820720527>3.0.co;2-n8242546
   PubMed Web of Science ®Google Scholar
• Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer. 1983;51(3):402–407. doi:10.1002/1097-0142(19830201)51:3<402::AID-CNCR2820510308>3.0.CO;2-P6571796
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Benjamin RS, Zimmerman S, et al. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res. 1983;43(2):917–920.6681533
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Yoshimura H, Iwata K, et al. [Distribution of pulsed intra arterial infusion chemotherapy in hepatic carcinomas]. Gan To Kagaku Ryoho. 1989;16(8 Pt 2):2991–2994.2551240
   PubMedGoogle Scholar
• Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006;30(6):445–451. doi:10.1007/s00264-006-0192-x16896870
   PubMed Web of Science ®Google Scholar